Search
FB-825
go.drugbank.com/drugs/DB17598InvestigationalIt is currently being investigated for immune disorders, such as atopic dermatitis and hyperimmunoglobulin E syndrome (HIES).[A258448,L45743]
Uproleselan
go.drugbank.com/drugs/DB14829InvestigationalUproleselan is a novel, specific E-Selectin antagonist under investigation in clinical trial NCT02306291 (Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy
AZD8630
go.drugbank.com/drugs/DB19397InvestigationalAZD8630 is an experimental drug under investigation, as described in the Phase I clinical study titled "Randomised, Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics
Bemegride
go.drugbank.com/drugs/DB13740ExperimentalBemegride is a CNS stimulant that is used to induce convulsions in experimental animals. It has also been used as a respiratory stimulant and in the treatment of barbiturate overdose.
Kava
go.drugbank.com/drugs/DB01322ApprovedInvestigationalNutraceuticalWithdrawnCategories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesN-(4-carbamimidoylbenzyl)-1-(3-phenylpropanoyl)-L-prolinamide
go.drugbank.com/drugs/DB06942ExperimentalThis compound belongs to the alpha amino acid amides. These are amide derivatives of alpha amino acids. This medication targets the protein prothrombin.
Simurosertib
go.drugbank.com/drugs/DB16330InvestigationalSimurosertib is under investigation in clinical trial NCT03261947 (A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal
Chloric acid
go.drugbank.com/drugs/DB14150ApprovedCategories: Compounds used in a research, industrial, or household settingIR208
go.drugbank.com/drugs/DB05106InvestigationalIR208 is a synthetic T-Cell receptor peptide vaccine developed by Immune Response Corporation. … It contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-Cells in over 90% of MS patients. IR208 is currently undergoing Phase II studies in a 200-patient trial.